Cargando…

Humoral Immune Response to CoronaVac in Turkish Adults

While most approved vaccines are based on the viral spike protein or its immunogenic regions, inactivated whole-virion vaccines (e.g., CoronaVac) contain additional antigens that may enhance protection. This study analyzes short-term humoral responses against the SARS-CoV-2 spike (S1) and nucleocaps...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cosgun, Yasemin, Emanet, Nergis, Kamiloglu, Ayten Öz, Grage-Griebenow, Evelin, Hohensee, Susann, Saschenbrecker, Sandra, Steinhagen, Katja, Korukluoglu, Gulay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967599/ https://www.ncbi.nlm.nih.gov/pubmed/36851093 http://dx.doi.org/10.3390/vaccines11020216

Ejemplares similares

Boosting immunity after CoronaVac
por: Sester, Martina, et al.
Publicado: (2022)

Minimal change disease following vaccination with CoronaVac
por: Dirim, Ahmet Burak, et al.
Publicado: (2021)

Immunogenicity of Mix-and-Match CoronaVac/BNT162b2 Regimen versus Homologous CoronaVac/CoronaVac Vaccination: A Single-Blinded, Randomized, Parallel Group Superiority Trial
por: Samoud, Samar, et al.
Publicado: (2023)

CoronaVac efficacy data from Turkey
por: McMenamin, Martina E, et al.
Publicado: (2021)

CoronaVac: more data for regulators and policy makers
por: Ramasamy, Maheshi N, et al.
Publicado: (2021)

ANCA-associated vasculitis following the CoronaVac vaccination
por: Ma, Yaohui, et al.
Publicado: (2022)

Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
por: Li, Jingxin, et al.
Publicado: (2022)

Humoral and cellular immune responses to CoronaVac up to one year after vaccination
por: Costa, Priscilla Ramos, et al.
Publicado: (2022)

CoronaVac efficacy data from Turkey – Authors' reply
por: Tanriover, Mine Durusu, et al.
Publicado: (2021)

Leukocytoclastic vasculitis after the third dose of CoronaVac vaccination
por: Oskay, T., et al.
Publicado: (2021)

Effectiveness of CoronaVac in preventing COVID-19 in healthcare workers
por: Bayhan, Gulsum Iclal, et al.
Publicado: (2022)

Antibody dynamics post-Comirnaty and CoronaVac vaccination in Malaysia
por: Tan, Cheng Siang, et al.
Publicado: (2022)

Cutaneous reactions after CoronaVac and BioNTech vaccines
por: Öner, Ümran, et al.
Publicado: (2022)

A Randomized Clinical Trial Using CoronaVac or BNT162b2 Vaccine as a Third Dose in Adults Vaccinated with Two Doses of CoronaVac
por: Mok, Chris Ka Pun, et al.
Publicado: (2022)

Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination
por: Costa, Priscilla Ramos, et al.
Publicado: (2022)

Evaluation and follow-up of antibody formation after CoronaVac vaccine
por: Çalişir, Büşra, et al.
Publicado: (2022)

Phenotypic and functional changes of T cell subsets after CoronaVac vaccination
por: Phoksawat, Wisitsak, et al.
Publicado: (2022)

Anaphylaxis is rare due to CoronaVac in a population of healthcare workers
por: Öztürk, Betül Özdel, et al.
Publicado: (2022)

Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine
por: Cao, Yunlong, et al.
Publicado: (2021)

Comparative Safety and Effectiveness of Heterologous CoronaVac–ChAdOx1 versus Homologous CoronaVac Vaccination in a Real-World Setting: A Retrospective Cohort Study
por: Ruenkham, Ayakarn, et al.
Publicado: (2023)

BNT162b2 or CoronaVac as the Third Dose against Omicron: Neutralizing Antibody Responses among Transplant Recipients Who Had Received Two Doses of CoronaVac
por: Erol, Çiğdem, et al.
Publicado: (2023)

Reduced CoronaVac vaccine antibody response in patients with chronic kidney disease
por: Akpolat, Tekin
Publicado: (2021)

CoronaVac or BNT162b2 Vaccine as a Third Dose
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Neutralizing antibodies induced by homologous and heterologous boosters in CoronaVac vaccines in Chile
por: Acevedo, Johanna, et al.
Publicado: (2023)

Longitudinal evaluation of innate immune responses to three doses of CoronaVac vaccine
por: Cao, Cheng, et al.
Publicado: (2023)

Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2
por: Rammauro, Florencia, et al.
Publicado: (2022)

Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy
por: Karacin, Cengiz, et al.
Publicado: (2021)

CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes
por: Laisuan, Wannada, et al.
Publicado: (2021)

Effectiveness of the CoronaVac® vaccine in a region of the Colombian Amazon, was herd immunity achieved?
por: Serrano-Coll, Héctor, et al.
Publicado: (2022)

Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil
por: Cerqueira-Silva, Thiago, et al.
Publicado: (2022)

Breakthrough COVID-19 case after full-dose administration of CoronaVac vaccine
por: Ulhaq, Zulvikar Syambani, et al.
Publicado: (2021)

Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study
por: Netto, Lucas C, et al.
Publicado: (2022)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
por: Goh, Yun Shan, et al.
Publicado: (2022)

Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents
por: Wang, Lei, et al.
Publicado: (2022)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
Publicado: (2023)

Longitudinal analysis of memory Tfh cells and antibody response following CoronaVac vaccination
por: Zhou, Pengcheng, et al.
Publicado: (2023)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
por: Çulpan, Hazal Cansu, et al.
Publicado: (2023)

Dynamic of humoral response to SARS-CoV-2 anti-Nucleocapsid and Spike proteins after CoronaVac vaccination
por: Bochnia-Bueno, Lucas, et al.
Publicado: (2022)

Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19
por: Zhao, Wei, et al.
Publicado: (2022)

Le vaccin chinois CoronaVac® à l’épreuve contre placebo en Turquie
por: Manus, Jean-Marie
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jrpinpd06gq44376hi8ebu8b0t